drugset
drugset / Trial / NCT05068206

A Clinical Study to Compare the Efficacy and Safety of AK105 Plus Anlotinib and Capecitabine/Oxaliplatin (CapeOx) , Anlotinib Plus CapeOx, Bevacizumab Plus CapeOx

NCT05068206 ↗

Phase 2 Unknown 120 enrolled Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
RandomizedParallel-groupOpen-labelTreatment

Summary

A clinical study to compare the efficacy and safety of AK105 plus anlotinib and Capecitabine/Oxaliplatin (CapeOx) , anlotinib plus CapeOx, bevacizumab plus CapeOx. A total of 120 cases will be enrolled to the group.

Timeline

Start
2021-10-08
Primary completion
2023-12
Completion
2024-06

Drugs

EvaluationDrugModalityDoseRoute
Comparator Bevacizumab Monoclonal antibody — Intravenous
Subject Catequentinib Small molecule — Oral
Subject Penpulimab Monoclonal antibody — Intravenous
Background Capecitabine Small molecule — Oral
Background Oxaliplatin Small molecule — Intravenous

Indications

colorectal cancer